Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):1741-1745.
doi: 10.21037/tp-2025-346. Epub 2025 Aug 27.

Less may be enough: a transplant-free future for low-risk relapsed Hodgkin lymphoma

Christopher J Forlenza  1 , Sharon M Castellino  2   3
Affiliations
Editorial

Less may be enough: a transplant-free future for low-risk relapsed Hodgkin lymphoma

Christopher J Forlenza et al. Transl Pediatr. .
No abstract available

Keywords: Hodgkin lymphoma; autologous stem cell transplant (ASCT); relapse; transplant-free.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-2025-346/coif). C.J.F. received consulting fees from Bristol-Myers Squibb. S.M.C. receives current grant support from NCI (R50CA285492) (PI Castellino) and SeaGen Inc. (now Pfizer), and fees from Bristol Meyers Squibb and SeaGen Inc. for pediatric advisory board activities. S.M.C. is also on the Scientific Advisory Board for the Lymphoma Research Foundation and had a consulting role on American Cancer Society roundtable on hematologic cancers and is on the Board of Directors for the Leukemia and Lymphoma Society. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-4. 10.1016/0140-6736(93)92411-l - DOI - PubMed
    1. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71. 10.1016/S0140-6736(02)08938-9 - DOI - PubMed
    1. Satwani P, Ahn KW, Carreras J, et al. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant 2015;50:1416-23. 10.1038/bmt.2015.177 - DOI - PMC - PubMed
    1. Desai SH, Spinner MA, David K, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. Am J Hematol 2023;98:464-71. 10.1002/ajh.26827 - DOI - PMC - PubMed
    1. Daw S, Cole PD, Hoppe BS, et al. Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial. JAMA Oncol 2025;11:249-57. 10.1001/jamaoncol.2024.5627 - DOI - PMC - PubMed

LinkOut - more resources